Pregablin Capsule
Product Images NDC 33342-168

Product Visual Gallery

This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Pregablin (NDC 33342-168). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Macleods Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

232 (Formula)

A formula calculating creatinine clearance, involving age in years, weight in kilograms, serum creatinine in mg/dL, and a factor for female patients. It is a mathematical expression rather than a data table, used for clinical assessment.*

FDA Label Image

1 (Pregabalin 25mg 90s Bottle)

Pregabalin Capsules 25 mg oral dosage form packaging label from Macleods Pharmaceuticals Limited. The label indicates 90 capsules per container and includes storage instructions (20° to 25°C, with excursions allowed between 15° to 30°C), dispensing requirements, and manufacturer details for Macleods Pharma USA and Macleods Pharmaceuticals Ltd in India. The concentration of 25 mg pregabalin per capsule is prominently displayed.*

FDA Label Image

1 (Pregabalin 100mg 90s Bottle)

Pregabalin Capsules 100 mg capsule label by Macleods Pharmaceuticals Limited. The label indicates each capsule contains 100 mg Pregabalin. It includes storage instructions, pharmacist dispensing instructions, and manufacturer details for Macleods Pharma USA, Inc. and Macleods Pharmaceuticals Ltd. The package contains 90 capsules.*

FDA Label Image

1 (Pregabalin 150mg 90s Bottle)

Label for Pregabalin Capsules CV 150 mg by Macleods Pharmaceuticals, showing a 90-capsule package. The label includes storage instructions, dispensing information, manufacturer details for Macleods Pharma USA, Inc. and Macleods Pharmaceuticals Ltd India, and a note to keep out of reach of children.*

FDA Label Image

1 (Pregabalin 200mg 90s Bottle)

Pregabalin Capsules CV 200 mg oral capsules label by Macleods Pharmaceuticals Limited. The label includes instructions to dispense the enclosed medication guide to each patient, storage temperature range (20° to 25°C), and manufacturer details including Macleods Pharma USA, Inc. and Macleods Pharmaceuticals Ltd. The package contains 90 capsules, with a US DEA schedule classification of CV.*

FDA Label Image

1 (Pregabalin 225mg 90s Bottle)

Label for Pregabalin Capsules 225 mg, an oral human prescription drug by Macleods Pharmaceuticals Limited. The label indicates each capsule contains 225 mg of Pregabalin, with a package count of 90 capsules. It includes storage instructions (20° to 25°C), dispensing instructions for pharmacists, and manufacturer details for Macleods Pharma USA, Inc. and Macleods Pharmaceuticals Ltd., India. Barcodes and a boxed area labeled OPZ AREA are also visible.*

FDA Label Image

1 (Pregabalin 300mg 90s Bottle)

Label for Pregabalin Capsules CV 300 mg by Macleods Pharmaceuticals Limited. The label shows that each capsule contains 300 mg of Pregabalin and comes in a 90-capsule bottle. It includes storage instructions, dispensing guidance for pharmacists, and manufacturer details for Macleods Pharma USA, Inc. and Macleods Pharmaceuticals Ltd. India.*

FDA Label Image

1 (Pregabalin 50mg 90s Bottle)

Label for Pregabalin Capsules CV 50 mg by Macleods Pharmaceuticals Limited. The label specifies each capsule contains 50 mg Pregabalin USP, with 90 capsules per container. It includes storage instructions, pharmacist dispensing guidance, and manufacturer details for Macleods Pharma USA and Macleods Pharmaceuticals Ltd, India.*

FDA Label Image

1 (Pregabalin 75mg 90s Bottle)

Pregabalin Capsules CV 75 mg oral capsules label by Macleods Pharmaceuticals Limited. The label indicates the product contains pregabalin, USP 75 mg per capsule and specifies storage instructions and dispensing guidance. It also shows a package count of 90 capsules and includes manufacturer details for Macleods Pharma USA, Inc. and Macleods Pharmaceuticals Ltd. The label features barcodes and a pharmacist dispensing warning.*

FDA Label Image

Pregabalin-fig--02.jpg (Pregabalin Fig 02)

A line graph showing the percent of patients improved relative to percent improvement in pain from baseline. It compares Pregabalin 100 mg three times a day versus placebo, with the x-axis representing percent improvement in pain and the y-axis representing percent of patients improved.*

FDA Label Image

Pregabalin-fig--09.jpg (Pregabalin Fig 09)

This line graph depicts the percent of patients improved plotted against the percent improvement in pain from baseline. It compares the effects of Pregabalin at daily doses of 600 mg, 450 mg, and 300 mg, as well as placebo. Each dose is represented by a differently styled line, showing trends in patient improvement with increasing pain relief percentages.*

FDA Label Image

Pregabalin-fig--10.jpg (Pregabalin Fig 10)

A Kaplan-Meier survival curve graph comparing Pregabalin and placebo groups over 180 days. The y-axis shows the estimated percentage of subjects without LTR (loss to response), while the x-axis represents days. Pregabalin group shows consistently higher survival without LTR compared to placebo.*

FDA Label Image

Pregabalin-fig--11.jpg (Pregabalin Fig 11)

A line graph depicting the percent of subjects improved over various improvement thresholds from baseline to Week 12, comparing Pregabalin with placebo. The x-axis shows percent improvement thresholds from >0 to ≥90, while the y-axis shows the percent of subjects improved. Pregabalin demonstrates a higher percentage of subjects improved across all thresholds compared to placebo.*

FDA Label Image

Pregabalin-fig--12.jpg (Pregabalin Fig 12)

A Kaplan-Meier curve chart comparing the percent of subjects improved over time from baseline to week 16 for Pregabalin versus placebo. The x-axis shows percent improvement, and the y-axis shows percent of subjects improved. The chart includes two survival curves: one for Pregabalin and one for placebo, with Pregabalin showing consistently higher improvement rates over time.*

FDA Label Image

Pregabalin-fig-01.jpg (Pregabalin Fig 01)

A line graph showing the percent of patients improved plotted against percent improvement in pain from baseline for Pregabalin at doses of 25 mg, 100 mg, and 200 mg three times a day compared to placebo. The chart displays treatment efficacy trends across increasing pain improvement percentages.*

FDA Label Image

Pregabalin-fig-03.jpg (Pregabalin Fig 03)

A line graph depicting percent improvement in pain from baseline on the x-axis versus percent of patients improved on the y-axis. It compares results for Pregabalin 75 mg, 150 mg, and 300 mg taken two times a day, along with placebo, showing higher doses correspond to greater patient improvement.*

FDA Label Image

Pregabalin-fig-04.jpg (Pregabalin Fig 04)

A line graph comparing the percentage of patients improved versus the percent improvement in pain from baseline for Pregablin 200 mg three times a day, Pregablin 100 mg three times a day, and placebo. The y-axis represents the percent of patients improved, and the x-axis shows percent improvement in pain from baseline.*

FDA Label Image

Pregabalin-fig-05.jpg (Pregabalin Fig 05)

A line graph showing the percent improvement in pain from baseline on the x-axis and the percent of patients improved on the y-axis. The graph compares Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo groups, with Pregabalin 100 mg showing the highest patient improvement rates.*

FDA Label Image

Pregabalin-fig-06.jpg (Pregabalin Fig 06)

A bar chart comparing responder rates (%) across different dosages of Pregablin in two studies, Study E1 and Study E3. The x-axis lists dosages including placebo and varying mg/day amounts, while the y-axis shows responder rates from 0% to 60%. The chart illustrates increasing responder rates with higher Pregablin doses in both studies.*

FDA Label Image

Pregabalin-fig-07.jpg (Pregabalin Fig 07)

A dose-response chart depicting median percentage reduction in seizure frequency from baseline versus dose in mg/day for Pregablin. The graph shows data from four studies labeled E1 BID, E2 TID, E3 BID, and E3 TID, with dose ranges from 0 to 600 mg/day and corresponding seizure reduction increases. Significant p-values indicating statistical relevance are annotated.*

FDA Label Image

Pregabalin-fig-08.jpg (Pregabalin Fig 08)

A bar chart illustrating responder rates (%) for Pregablin at different dosages and placebo. The x-axis shows three groups: Placebo (93 participants), 2.5 mg/kg/day (103 participants), and 10 mg/kg/day (96 participants). The y-axis measures responder rate in percent, with values approximately 22.6% for placebo, 29.1% for 2.5 mg/kg/day, and 40.6% for 10 mg/kg/day.*

FDA Label Image

Pregabalin-struct.jpg (Pregabalin Struct)

Chemical structure of Pregablin showing the molecular arrangement including carboxylic acid (CO2H) and amino (NH2) functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.